英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

infuriate    音标拼音: [ɪnfj'ʊri,et]
a. 狂怒的
vt. 激怒

狂怒的激怒

infuriate
v 1: make furious [synonym: {infuriate}, {exasperate}, {incense}]

Infuriate \In*fu"ri*ate\, v. t. [imp. & p. p. {Infuriated}; p.
pr. & vb. n. {Infuriating}] [It. infuriato, p. p. of
infuriare; pref. in- (L. in) furia fury, L. furia. See
{Fury}.]
To render furious; to enrage; to exasperate.
[1913 Webster]

Those curls of entangled snakes with which Erinys is
said to have infuriated Athemas and Ino. --Dr. H. More.
[1913 Webster]


Infuriate \In*fu"ri*ate\, a. [It. infuriato, p. p. of infuriare.
See {Infuriate}, v. t.]
Enraged; raging; furiously angry; infuriated. --Milton.
[1913 Webster]

Inflamed beyond the most infuriate wrath. --Thomson.
[1913 Webster]

83 Moby Thesaurus words for "infuriate":
aggravate, agitate, alienate, anger, annoy, antagonize, arouse,
awake, awaken, blow the coals, blow up, bother, bug, burn up,
call forth, call up, chafe, embitter, enkindle, enrage, envenom,
estrange, exacerbate, exasperate, excite, fan, fan the fire,
fan the flame, feed the fire, fire, flame, foment, frenzy, gall,
heat, heat up, impassion, incense, incite, inflame, ire, irk,
irritate, key up, kindle, lash into fury, lather up,
light the fuse, light up, mad, madden, miff, move, nettle,
overexcite, peeve, pique, provoke, rile, rouse, set against,
set astir, set at odds, set fire to, set on fire, steam up, stir,
stir the blood, stir the embers, stir the feelings, stir up,
summon up, turn on, umbrage, vex, wake, wake up, waken, warm,
warm the blood, whip up, work into, work up


请选择你想看的字典辞典：
单词字典翻译
infuriate查看　infuriate　在百度字典中的解释百度英翻中〔查看〕
infuriate查看　infuriate　在Google字典中的解释Google英翻中〔查看〕
infuriate查看　infuriate　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Trastuzumab-deruxtecan and radiotherapy: a safety sub . . .
    The integration of Trastuzumab Deruxtecan (T-DXd) with radiotherapy (RT) in metastatic HER2-positive breast cancer demonstrates a favorable safety profile, with acceptable toxicity and promising progression-free survival outcomes for patients with oligoprogressive disease treated with SBRT These findings suggest that concurrent T-DXd and RT could be a feasible therapeutic approach for
  • FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab . . .
    On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc ) in combination with pertuzumab for the first-line treatment of
  • Enhertu Approved for Any HER2-Positive Solid Cancer
    On August 5, the agency gave an accelerated approval for trastuzumab deruxtecan —often called T-DXd—to treat anyone with any advanced solid cancer if their tumors produce high levels of the protein HER2, or HER2-positive To receive the drug, a patient must already have received at least one prior treatment
  • Patient Access to Treatment | ENHERTU4U
    Learn about programs to help you access and afford your prescribed ENHERTU® (fam-trastuzumab deruxtecan-nxki) 20mg ml Injection for Intravenous Use treatment
  • Safety and efficacy of combined trastuzumab-deruxtecan and . . .
    The standard treatment for newly diagnosed HER2-positive (HER2+) metastatic breast cancer is a combination of pertuzumab and trastuzumab (anti-HER2 antibodies) with taxanes [[3], [4], [5]] For patients whose disease progresses after this treatment, the standard second-line treatment is trastuzumab deruxtecan (T-DXd)
  • FDA approves fam-trastuzumab deruxtecan-nxki for breast cancer
    On January 27, 2025, the FDA approved fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
  • Trastuzumab Deruxtecan: Uses, Dosage, Side Effects, Warnings . . .
    Trastuzumab deruxtecan (Enhertu, T-DXd) is a treatment for breast cancer, advanced stomach cancer, non-small cell lung cancer, and solid tumors Includes side effects, FDA approval, package insert, and more
  • Enhertu (fam-trastuzumab deruxtecan-nxki) FDA Approval . . .
    FDA approval history for Enhertu (fam-trastuzumab deruxtecan-nxki) used to treat Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Solid Tumors Supplied by AstraZeneca and Daiichi Sankyo Company, Limited
  • About ENHERTU4U | ENHERTU® (fam-trastuzumab deruxtecan-nxki . . .
    HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer
  • Fam-trastuzumab deruxtecan-nxki (Enhertu®) for Breast Cancer . . .
    How does fam-trastuzumab deruxtecan-nxki (Enhertu®) work? Enhertu® targets a protein on the surface of breast cancer cells known as H uman E pidermal growth factor R eceptor 2 (HER-2) Once Enhertu® binds to the breast cancer cell, it enter the cell and releases a molecule called deruxtecan (DXd), a type of topoisomerase-I inhibitor designed to stop breast cancer cells from growing and





中文字典-英文字典  2005-2009